| 证券代码：300677 | 证券简称：英科医疗 | 公告编号：2025-115 | | --- | --- | --- | | 债券代码：123029 | 债券简称：英科转债 | | 5、"英科转债"最后转股日：2025 年 8 月 15 日； 6、"英科转债"最后交易日为 2021 年 6 月 28 日，已于 2021 年 6 月 29 日停止交易。在停止交易后、转股期结束前（即 2021 年 6 月 29 日至 2025 年 8 月 15 日），"英科转债"持有人仍可以依据约定 的条件，将"英科转债"转换为公司股票，目前转股价格为人民币 3.42 元/股。 英科医疗科技股份有限公司 关于英科转债到期兑付及摘牌的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、"英科转债"到期日及兑付登记日：2025 年 8 月 15 日； 2、"英科转债"到期兑付价格：128 元人民币/张（含最后一期 利息）； 3、"英科转债"到期兑付资金发放日：2025 年 8 月 18 日； 4、"英科转债"摘牌日：2025 年 8 月 18 日； 一、"英科 ...

Trading Information Summary - On August 8, 2025, the main funds of Yingke Medical experienced a net outflow of 43.40 million yuan, while speculative funds saw a net outflow of 16.28 million yuan. In contrast, retail investors had a net inflow of 59.68 million yuan [1][3]. Company Announcement Summary - Yingke Medical Technology Co., Ltd. issued its seventh reminder announcement regarding the upcoming maturity and redemption of Yingke Convertible Bonds. The bonds are set to mature on August 15, 2025, with a redemption price of 128 yuan per bond, including the last interest payment. The final conversion date is also August 15, 2025, with a conversion price of 3.42 yuan per share [1][3]. - The company issued 4.70 million convertible bonds in August 2019, with a total issuance amount of 470 million yuan. The bonds have been in the conversion period since February 24, 2020, and will continue until August 15, 2025. The company has committed to publishing relevant announcements regarding the maturity and delisting of the bonds on the designated information disclosure website [1].

Group 1 - The stock price of Yingke Medical closed at 37.58 yuan on August 8, down 0.84 yuan, a decrease of 2.19% from the previous trading day. The opening price was 38.12 yuan, with a high of 38.40 yuan and a low of 36.68 yuan. The trading volume was 232,400 hands, with a transaction amount of 871 million yuan [1] - Yingke Medical's main business includes the research, production, and sales of disposable gloves, wheelchairs, and other medical protective products, which are widely used in medical care, food processing, and electronics industries [1] - In the first quarter of 2025, the company achieved operating revenue of 2.494 billion yuan and a net profit of 353 million yuan [1] Group 2 - On August 8, the controlling shareholder Liu Fangyi pledged 16.3 million shares, accounting for 7.03% of his holdings. As of the announcement date, the total pledged shares reached 22.1 million, representing 9.54% of his holdings [1] - On August 8, the net outflow of main funds for Yingke Medical was 43.4 million yuan, accounting for 0.25% of the circulating market value. Over the past five trading days, the cumulative net outflow was 85.3 million yuan, representing 0.49% of the circulating market value [1]

金融界消息 截至2025年8月8日收盘，英科医疗（300677）报收于37.58元，下跌2.19%，换手率5.0%， 成交量23.24万手，成交金额8.71亿元。 英科医疗最新一期业绩显示，截至2025一季报，公司营业总收入24.94亿元、同比增长13.20%，归属净 利润3.53亿元，同比增长48.08%，扣非净利润2.47亿元，同比增长53.22%，流动比率1.432、速动比率 1.357、资产负债率51.61%。 天眼查商业履历信息显示，英科医疗科技股份有限公司，成立于2009年，位于淄博市，是一家以从事医 药制造业为主的企业。企业注册资本65081.5948万人民币，实缴资本6350万人民币。公司法定代表人为 刘方毅。 通过天眼查大数据分析，英科医疗科技股份有限公司共对外投资了30家企业，参与招投标项目56次，知 识产权方面有商标信息125条，专利信息53条，此外企业还拥有行政许可26个。 来源：金融界 资金流向方面，今日主力资金净流出4340.03万元，占比成交额4.98%。其中，超大单净流入2964.16万 元、占成交额3.4%，大单净流出7304.19万元、占成交额8.39%，中单净流出流出16 ...

Core Insights - The strategic cooperation agreement was signed between Yingke Medical and Charoen Pokphand Group's Bee Selection in China, marking a significant milestone for both companies in enhancing safety standards in the food and agriculture sector [1][3]. Group 1: Partnership Details - Yingke Medical will supply over 20 types of professional protective products, including disposable nitrile gloves, PVC gloves, synthetic latex gloves, PE gloves, and disposable caps, to Charoen Pokphand Group's food production, livestock slaughtering, and animal health sectors [3]. - The collaboration aims to leverage Yingke Medical's 30 years of experience in the protective equipment field, which has served over 10,000 global clients, ensuring that the products meet the stringent safety and hygiene standards required by Charoen Pokphand Group [3][5]. Group 2: Safety Ecosystem Development - The partnership extends beyond product supply to a deep integration of resources, focusing on building a "safety ecosystem" that includes customized protective solutions for various operational scenarios such as food processing and livestock disease prevention [5]. - This collaboration is expected to enhance Charoen Pokphand Group's safety production system and improve supply chain risk management and overall efficiency [5]. Group 3: Future Outlook - Both companies expressed their commitment to exploring deeper collaborative models, aiming for mutual benefits and a win-win situation [5][7]. - The partnership is seen as a necessary outcome of market resource optimization and a practical example of industrial collaborative development, with the goal of upgrading safety standards in China's agriculture and food industry [7].

Core Viewpoint - The company Inke Medical is experiencing a decline in stock price and has a lower price-to-earnings (PE) ratio compared to the industry average, indicating potential undervaluation in the medical device sector [1][2]. Company Summary - Inke Medical's stock closed at 37.58 yuan, down 2.19%, with a rolling PE ratio of 15.57 times and a total market capitalization of 24.603 billion yuan [1]. - The company specializes in the research, production, and sales of high-performance personal protective products, including disposable nitrile gloves, PVC gloves, isolation gowns, masks, and various medical equipment [1]. - For Q1 2025, Inke Medical reported revenue of 2.494 billion yuan, a year-on-year increase of 13.20%, and a net profit of 353 million yuan, reflecting a year-on-year growth of 48.08% with a gross profit margin of 24.16% [1]. Industry Summary - The average PE ratio for the medical device industry is 55.70 times, with a median of 39.08 times, positioning Inke Medical at the 33rd rank within the industry [1][2]. - The industry shows a significant variation in PE ratios, with other companies like Jiuan Medical at 11.14 times and Shandong Pharmaceutical Glass at 16.06 times, indicating a diverse valuation landscape [2].

证券代码：300677 证券简称：英科医疗 公告编号：2025-114 | | | 股东 名称 是否为控 股股东或 第一大股 东及其一 致行动人 本次质押股 数（股） 占其所 持股份 比例 占公司 总股本 比例 是否 为限 售股 是否 为补 充质 押 质押起 始日 质押到 期日 质权人 质押 用途 刘方毅 是 16,300,000 7.03% 2.49% 是，高 管锁定 股 否 2025 年 08 月 07 日 2028 年 08 月 04 日 国金证券资 产管理有限 公司 个人资 金需求 一、股东本次股份质押的基本情况 | 称 | （股） | 例 | 押前质 | 后质押股 | 所持 | 司总 | 已质押股 | 占已 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 押股份 | 份数量 | 股份 | 股本 | 份限售和 | 质押 | 未质押股份 | 占未质 | | | | | 数量 | （股） | 比例 | 比例 | 冻结、标 | 股份 | 限售和冻结 | 押股份 | | | | | （股） | ...

| 证券代码：300677 | 证券简称：英科医疗 公告编号：2025-113 | | --- | --- | | 债券代码：123029 | 债券简称：英科转债 | 英科医疗科技股份有限公司 经中国证券监督管理委员会"证监许可[2019]1183 号"文核准， 公司于 2019 年 8 月 16 日公开发行了 470 万张可转债，每张面值 100 元，发行总额 4.70 亿元。 关于英科转债即将到期暨赎回的第七次提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、"英科转债"到期日：2025 年 8 月 15 日； 2、"英科转债"到期兑付价格：128 元人民币/张（含最后一期 利息）； 3、"英科转债"最后转股日：2025 年 8 月 15 日； 4、"英科转债"最后交易日为 2021 年 6 月 28 日，已于 2021 年 6 月 29 日停止交易。在停止交易后、转股期结束前（即 2021 年 6 月 29 日至 2025 年 8 月 15 日），"英科转债"持有人仍可以依据约定 的条件，将"英科转债"转换为公司股票，目前转股价 ...

Core Insights - The company Inke Medical closed at 38.42 yuan on August 7, with a 1.53% increase, resulting in a rolling PE ratio of 15.92 times and a total market capitalization of 25.153 billion yuan [1] - Inke Medical ranks 33rd in the medical device industry, which has an average PE ratio of 54.79 times and a median of 37.86 times [1] - The company experienced a net outflow of 33.9538 million yuan in principal funds on August 7, with a total outflow of 27.1491 million yuan over the past five days [1] Company Overview - Inke Medical specializes in the research, development, production, and sales of high-performance personal protective products [1] - The main products include disposable nitrile gloves, disposable PVC gloves, disposable PE gloves, isolation gowns, masks, electric wheelchairs, manual wheelchairs, mobility scooters, walkers, electric sofas, medical bedside tables, ice/hot packs, hand sanitizers, heating pads, cooling pads, and ECG electrodes [1] Financial Performance - For the first quarter of 2025, Inke Medical reported an operating income of 2.494 billion yuan, a year-on-year increase of 13.20%, and a net profit of 353 million yuan, a year-on-year increase of 48.08%, with a gross profit margin of 24.16% [1]

Core Viewpoint - The medical sector in A-shares is experiencing a resurgence, with the largest medical ETF (512170) rising by 2% in early trading on August 7, 2023, and quickly surpassing a transaction volume of 400 million yuan [1]. Group 1: Market Performance - The medical device sector is leading the gains, with stocks like Furuide (福瑞股份) rising nearly 8%, and Huada Zhizao (华大智造) and Yingke Medical (英科医疗) increasing over 6% [1]. - The CXO sector is underperforming, with WuXi AppTec (药明康德) and Zhaoyan New Drug (昭衍新药) both declining by over 1% [1]. Group 2: Industry Trends - The 11th batch of national drug procurement has officially started, involving 55 products that are all mature and competitive, with an emphasis on optimizing procurement rules and adhering to the principle of "anti-involution" [1]. - Citic Securities reports that recent high-level discussions have emphasized principles such as "anti-involution" and "procurement optimization not solely based on low prices," signaling a turning point for the innovative drug and medical device industry [3]. - Citic Jin Investment highlights that increasing international business opportunities in the medical device sector are expected to drive high growth for several companies by 2025, leading to a potential revaluation of these companies [3]. Group 3: Investment Opportunities - Some fund managers believe that the market trend this year may favor medical devices after pharmaceuticals, suggesting that the previously underperforming medical device sector may see a rebound [3]. - The largest medical ETF (512170) is recommended for capturing upward opportunities in the medical device and CXO sectors, focusing on "medical devices + medical services" and being highly correlated with AI medical applications [3].